Glucocorticoid pharmacogenetics in pediatric idiopathic nephrotic syndrome

Pharmacogenomics

Volumn 16, Issue 14, 2015, Pages 1631-1648

  Cuzzoni, Eva ^a   De Iudicibus, Sara ^b   Franca, Raffaella ^b   Stocco, Gabriele ^a   Lucafò, Marianna ^a   Pelin, Marco ^a   Favretto, Diego ^b   Pasini, Andrea ^c   Montini, Giovanni ^d   Decorti, Giuliana ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

glucocorticoid receptor; glucocorticoid receptor heterocomplex; glucocorticoids; idiopathic nephrotic syndrome; inflammatory mediators; P gp; polymorphisms

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 3A5; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MULTIDRUG RESISTANCE PROTEIN; PREDNISOLONE; PREDNISONE; PROTEIN P23; TATA BINDING PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; BINDING SITE; BODY COMPOSITION; CD2AP GENE; COMPLEX FORMATION; CYTOKINE RELEASE; DNA POLYMORPHISM; DRUG EFFICACY; EXON; GENE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRON; NEPHROTIC SYNDROME; NPHS1 GENE; NPHS2 GENE; NR3C1 GENE; NUCLEAR LOCALIZATION SIGNAL; PHARMACOGENETICS; PLCE1 GENE; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN MOTIF; REMISSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; WT1 GENEE; CHILD; GENETICS;

CHILD; GLUCOCORTICOIDS; HUMANS; NEPHROTIC SYNDROME; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84945563711     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.101     Document Type: Review

References (154)

1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 362(9384), 629-639 (2003).
2. Gipson DS, Massengill SF, Yao L et al. Management of childhood onset nephrotic syndrome. Pediatrics 124(2), 747-757 (2009).
3. Joshi S, Andersen R, Jespersen B, Rittig S. Genetics of steroid-resistant nephrotic syndrome: a review of mutation spectrum and suggested approach for genetic testing. Acta Paediatr. 102(9), 844-856 (2013).
4. Mekahli D, Liutkus A, Ranchin B et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study Pediatr. Nephrol. 24(8), 1525-1532 (2009).
5. Reidy K, Kaskel FJ. Pathophysiology of focal segmental glomerulosclerosis. Pediatr. Nephrol. 22(3), 350-354 (2007).
6. Evans WE, Mcleod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
7. Escriva H, Delaunay F, Laudet V. Ligand binding and nuclear receptor evolution. Bioessays 22(8), 717-727 (2000).
8. Muller-Berghaus J, Kemper MJ, Hoppe B et al. The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. Nephrol. Dial. Transplant. 23(12), 3841-3844 (2008).
9. Detera-Wadleigh SD, Encio IJ, Rollins DY, Coffman D, Wiesch D. A TthIII1 polymorphism on the 5' fanking region of the glucocorticoid receptor gene (GRL). Nucleic Acids Res. 19(8), 1960 (1991).
10. Pemberton LF, Paschal BM. Mechanisms of receptor-mediated nuclear import and nuclear export. Traffc 6(3), 187-198 (2005).
11. Nordeen SK, Suh BJ, Kuhnel B, Hutchison CA 3rd. Structural determinants of a glucocorticoid receptor recognition element. Mol. Endocrinol. 4(12), 1866-1873 (1990).
12. Catley M. Dissociated steroids. Sci. World J. 7, 421-430 (2007).
13. Ehrchen J, Steinmuller L, Barczyk K et al. Glucocorticoids induce differentiation of a specifcally activated, antiinfammatory subtype of human monocytes. Blood 109(3), 1265-1274 (2007).
14. Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl Acad. Sci. USA 101(1), 227-232 (2004).
15. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96(1), 23-43 (2002).
16. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell Endocrinol. 275(1-2), 71-78 (2007).
17. Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 73(9-10), 1025-1029 (2008).
18. Truss M, Beato M. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 14(4), 459-479 (1993).
19. Adcock IM. Glucocorticoid-regulated transcription factors. Pulm. Pharmacol. Ther. 14(3), 211-219 (2001).
20. Barnes PJ, Adcock IM. Nf-kappa B. A pivotal role in asthma and a new target for therapy Trends Pharmacol. Sci. 18(2), 46-50 (1997).
21. Miner JN, Yamamoto KR. The basic region of AP-1 specifes glucocorticoid receptor activity at a composite response element. Genes Dev. 6(12B), 2491-2501 (1992).
22. Yang-Yen HF, Chambard JC, Sun YL et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62(6), 1205-1215 (1990).
23. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl Acad. Sci. USA 91(2), 752-756 (1994).
24. Alangari AA. Genomic and non-genomic actions of glucocorticoids in asthma. Ann. Thorac. Med. 5(3), 133-139 (2010).
25. Theriault A, Boyd E, Harrap SB, Hollenberg SM, Connor JM. Regional chromosomal assignment of the human glucocorticoid receptor gene to 5q31. Hum. Genet. 83(3), 289-291 (1989).
26. De Iudicibus S, Stocco G, Martelossi S et al. Genetic predictors of glucocorticoid response in pediatric patients with infammatory bowel diseases. J. Clin. Gastroenterol. 45(1), e1-e7 (2011).
27. Manenschijn L, Van Den Akker EL, Lamberts SW, Van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann. NY Acad. Sci. 1179, 179-198 (2009).
28. Rosmond R, Chagnon YC, Chagnon M, Perusse L, Bouchard C, Bjorntorp P. A polymorphism of the 5'-fanking region of the glucocorticoid receptor gene locus is associated with basal cortisol secretion in men. Metabolism 49(9), 1197-1199 (2000).
29. Huizenga NA, Koper JW, De Lange P et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J. Clin. Endocrinol. Metab. 83(1), 144-151 (1998).
30. Di Blasio AM, Van Rossum EF, Maestrini S et al. The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients. Clin. Endocrinol. (Oxf.) 59(1), 68-74 (2003).
31. Panarelli M, Holloway CD, Fraser R et al. Glucocorticoid receptor polymorphism, skin vasoconstriction, and other metabolic intermediate phenotypes in normal human subjects. J. Clin. Endocrinol. Metab. 83(6), 1846-1852 (1998).
32. Oretti C, Marino S, Mosca F et al. Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome. Eur. J. Clin. Pharmacol. 65(5), 483-491 (2009).
33. Marino S, Verzegnassi F, Tamaro P et al. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr. Blood. Cancer 53(6), 984-991 (2009).
34. Van Winsen LM, Manenschijn L, Van Rossum EF et al. A glucocorticoid receptor gene haplotype (TthIII1/ER22/23EK/9beta) is associated with a more aggressive disease course in multiple sclerosis. J. Clin. Endocrinol. Metab. 94 (6), 2110-2114 (2009).
35. Szabo V, Borgulya G, Filkorn T, Majnik J, Banyasz I, Nagy ZZ. The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in hungarian patients treated with photorefractive keratectomy. Mol. Vis. 13, 659-666 (2007).
36. Bonifati DM, Witchel SF, Ermani M, Hoffman EP, Angelini C, Pegoraro E. The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. J. Neurol. Neurosurg. Psychiatry 77(10), 1177-1179 (2006).
37. De Iudicibus S, Stocco G, Martelossi S et al. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in infammatory bowel disease. Gut 56(9), 1319-1321 (2007).
38. De Lange P, Koper JW, Huizenga NA et al. Differential hormone-dependent transcriptional activation and-repression by naturally occurring human glucocorticoid receptor variants. Mol. Endocrinol. 11(8), 1156-1164 (1997).
39. Derijk RH, Schaaf MJ, Turner G et al. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mrna is associated with rheumatoid arthritis. J. Rheumatol. 28(11), 2383-2388 (2001).
40. Van Den Akker EL, Russcher H, Van Rossum EF et al. Glucocorticoid receptor polymorphism affects transrepression but not transactivation. J. Clin. Endocrinol. Metab. 91(7), 2800-2803 (2006).
41. Van Rossum EF, Koper JW, Van Den Beld AW et al. Identifcation of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin. Endocrinol. 59(5), 585-592 (2003).
42. Zalewski G, Wasilewska A, Zoch-Zwierz W, Chyczewski L. Response to prednisone in relation to NR3C1 intron B polymorphisms in childhood nephrotic syndrome. Pediatr. Nephrol. 23(7), 1073-1078 (2008).
43. Cho HY, Choi HJ, Lee SH et al. Polymorphisms of the NR3C1 gene in korean children with nephrotic syndrome. Korean J. Pediatr. 52(11), 1260-1266 (2009).
44. Teeninga N, Kist-Van Holthe JE, Van Den Akker EL et al. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int. 85 (6), 1444-1453 (2014).
45. Honda M, Orii F, Ayabe T et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118(5), 859-866 (2000).
46. Fujishima S, Takeda H, Kawata S, Yamakawa M. The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. Clin. Immunol. 133(2), 208-217 (2009).
47. Lewis-Tuffn LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann. NY Acad. Sci. 1069, 1-9 (2006).
48. Zhang X, Clark AF, Yorio T. Regulation of glucocorticoid responsiveness in glaucomatous trabecular meshwork cells by glucocorticoid receptor-beta. Invest Ophthal. Mol. Vis. Sci. 46(12), 4607-4616 (2005).
49. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Ex.p Eye Res. 84(2), 275-284 (2007).
50. Liu Y, Song L, Li B. The expression of glucocorticoid receptor beta messenger rna in peripheral white blood cells of hormone-resistant nephrotic syndrome patients. Zhonghua Nei Ke Za Zhi 40(11), 725-728 (2001).
51. Szilagyi K, Podracka L, Franke NE, Mojzis J, Mirossay L. A new link between steroid resistance, glucocorticoid receptor and nuclear factor kappa b p65 in idiopathic nephrotic syndrome. Neuro Endocrinol. Lett. 30(5), 629-636 (2009).
52. Ye J, Yu Z, Ding J et al. Genetic variations of the nr3c1 gene in children with sporadic nephrotic syndrome. Biochem. Biophys. Res. Commun. 348(2), 507-513 (2006).
53. De Iudicibus S, Franca R, Martelossi S, Ventura A, Decorti G. Molecular mechanism of glucocorticoid resistance in infammatory bowel disease. World J. Gastroenterol. 17(9), 1095-1108 (2011).
54. Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol. Cell Endocrinol. 300(1-2), 7-16 (2009).
55. Ouyang J, Jiang T, Tan M, Cui Y, Li X. Abnormal expression and distribution of heat shock protein 90: potential etiologic immunoendocrine mechanism of glucocorticoid resistance in idiopathic nephrotic syndrome. Clin. Vaccine Immunol. 13(4), 496-500 (2006).
56. Ouyang J, Chen P, Jiang T, Chen Y, Li J. Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephrotic syndrome. Int. Immunopharmacol. 14(3), 334-340 (2012).
57. Maltese P, Palma L, Sfara C et al. Glucocorticoid resistance in crohn's disease and ulcerative colitis: an association study investigating gr and FKBP5 gene polymorphisms. Pharmacogenomics J. 12(5), 432-438 (2012).
58. Hawkins GA, Lazarus R, Smith RS et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J. Allergy Clin. Immunol. 123(6), 1376-1383 e1377 (2009).
59. Hakim A, Barnes PJ, Adcock IM, Usmani OS. Importin-7 mediates glucocorticoid receptor nuclear import and is impaired by oxidative stress, leading to glucocorticoid insensitivity. FASEB J. 27(11), 4510-4519 (2013).
60. Freedman ND, Yamamoto KR. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol. Biol. Cell 15(5), 2276-2286 (2004).
61. Tao T, Lan J, Lukacs GL, Hache RJ, Kaplan F. Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 35(6), 668-680 (2006).
62. Haas DM, Dantzer J, Lehmann AS et al. The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. Am. J. Obstet. Gynecol. 208 (3), 215 e211-e216 (2013).
63. Raby BA, Van Steen K, Lasky-Su J, Tantisira K, Kaplan F, Weiss ST. Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma. Respir. Res. 10, 67 (2009).
64. Araya CE, Wasserfall CH, Brusko TM et al. A case of unfulflled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 21(5), 603-610 (2006).
65. Raveh D, Shemesh O, Ashkenazi YJ, Winkler R, Barak V. Tumor necrosis factor-alpha blocking agent as a treatment for nephrotic syndrome. Pediatr. Nephrol. 19(11), 1281-1284 (2004).
66. Leroy S, Guigonis V, Bruckner D et al. Successful anti-TNFalpha treatment in a child with posttransplant recurrent focal segmental glomerulosclerosis. Am. J. Transplant. 9(4), 858-861 (2009).
67. Jaiswal A, Prasad N, Agarwal V et al. Regulatory and effector T cells changes in remission and resistant state of childhood nephrotic syndrome. Indian J. Nephrol. 24(6), 349-355 (2014).
68. Prasad N, Jaiswal AK, Agarwal V et al. Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in childhood nephrotic syndrome: a longitudinal study. Cytokine 72(2), 190-196 (2015).
69. Galon J, Franchimont D, Hiroi N et al. Gene profling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16(1), 61-71 (2002).
70. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function∗. Annu. Rev. Immunol. 18, 309-345 (2000).
71. Pype JL, Dupont LJ, Menten P et al. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am. J. Respir. Cell Mol. Biol. 21(4), 528-536 (1999).
72. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway infammation with eosinophilia. J. Immunol. 163 (3), 1545-1551 (1999).
73. Niemir ZI, Stein H, Dworacki G et al. Podocytes are the major source of IL-1 alpha and IL-1 beta in human glomerulonephritides. Kidney Int. 52(2), 393-403 (1997).
74. Saxena S, Mittal A, Andal A. Pattern of interleukins in minimal-change nephrotic syndrome of childhood. Nephron 65(1), 56-61 (1993).
75. Chen W P, Lin CY. Augmented expression of interleukin-6 and interleukin-1 genes in the mesangium of IgM mesangial nephropathy. Nephron 68(1), 10-19 (1994).
76. Suranyi MG, Guasch A, Hall BM, Myers BD. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am. J. Kidney Dis. 21(3), 251-259 (1993).
77. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur. J. Clin. Invest. 22(6), 396-402 (1992).
78. Haukim N, Bidwell JL, Smith AJ et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun. 3(6), 313-330 (2002).
79. Markova S, Nakamura T, Makimoto H et al. IL-1beta genotype-related effect of prednisolone on IL-1beta production in human peripheral blood mononuclear cells under acute infammation. Biol. Pharm. Bull. 30 (8), 1481-1487 (2007).
80. Hamacher R, Diersch S, Scheibel M et al. Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer. Cytokine 46(2), 182-186 (2009).
81. Hall SK, Perregaux DG, Gabel CA et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum. 50 (6), 1976-1983 (2004).
82. Kobayashi M, Fitz L, Ryan M et al. Identifcation and purifcation of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170(3), 827-845 (1989).
83. Lin CY, Chien J W. Increased interleukin-12 release from peripheral blood mononuclear cells in nephrotic phase of minimal change nephrotic syndrome. Acta Paediatr. Taiwan 45(2), 77-80 (2004).
84. Matsumoto K, Kanmatsuse K. Increased IL-12 release by monocytes in nephrotic patients. Clin. Exp. Immunol. 117(2), 361-367 (1999).
85. Matsumoto K, Kanmatsuse K. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron 85(2), 127-133 (2000).
86. Stefanovic V, Golubovic E, Mitic-Zlatkovic M, Vlahovic P, Jovanovic O, Bogdanovic R. Interleukin-12 and interferon-gamma production in childhood idiopathic nephrotic syndrome. Pediatr. Nephrol. 12(6), 463-466 (1998).
87. Muller-Berghaus J, Kern K, Paschen A et al. Defcient IL-12p70 secretion by dendritic cells based on IL12b promoter genotype. Genes Immun. 5(5), 431-434 (2004).
88. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491-503 (1994).
89. De Beaucoudrey L, Samarina A, Bustamante J et al. Revisiting human IL-12rbeta1 defciency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 89(6), 381-402 (2010).
90. Carroll MC, Katzman P, Alicot EM et al. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc. Natl Acad. Sci. USA 84(23), 8535-8539 (1987).
91. Harney S, Newton J, Milicic A, Brown MA, Wordsworth BP. Non-inherited maternal HLA alleles are associated with rheumatoid arthritis. Rheumatology 42(1), 171-174 (2003).
92. Bustos C, Gonzalez E, Muley R, Alonso JL, Egido J. Increase of tumour necrosis factor alpha synthesis and gene expression in peripheral blood mononuclear cells of children with idiopathic nephrotic syndrome. Eur. J. Clin. Invest. 24(12), 799-805 (1994).
93. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha-308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim. Biophys. Acta 1792(3), 163-172 (2009).
94. Wilson AG, De Vries N, Pociot F, Di Giovine FS, Van Der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J. Exp. Med. 177(2), 557-560 (1993).
95. Kim SD, Park JM, Kim IS et al. Association of IL-1beta, IL-1ra, and TNF-alpha gene polymorphisms in childhood nephrotic syndrome. Pediatr. Nephrol. 19(3), 295-299 (2004).
96. Jafar T, Agrawal S, Mahdi AA, Sharma RK, Awasthi S, Agarwal GG. Cytokine gene polymorphism in idiopathic nephrotic syndrome children. Indian J. Clin. Biochem. 26(3), 296-302 (2011).
97. Tripathi G, Jafar T, Mandal K et al. Does cytokine gene polymorphism affect steroid responses in idiopathic nephrotic syndrome? Indian J. Med. Sci. 62(10), 383-391 (2008).
98. Lan HY, Yang N, Nikolic-Paterson DJ et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 57(2), 499-509 (2000).
99. Nohara H, Okayama N, Inoue N et al. Association of the-173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J. Gastroenterol. 39(3), 242-246 (2004).
100. Bernhagen J, Calandra T, Mitchell RA et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365(6448), 756-759 (1993).
101. Donn R, Alourf Z, De Benedetti F et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 46(9), 2402-2409 (2002).
102. Donn R, Alourf Z, Zeggini E et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 50(5), 1604-1610 (2004).
103. Lolis E. Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery Curr. Opin. Pharmacol. 1(6), 662-668 (2001).
104. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3(10), 791-800 (2003).
105. Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A. Association of macrophage migration inhibitory factor-173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr. Nephrol. 20(11), 1566-1571 (2005).
106. Vivarelli M, D'urbano LE, Stringini G et al. Association of the macrophage migration inhibitory factor-173∗C allele with childhood nephrotic syndrome. Pediatr. Nephrol. 23(5), 743-748 (2008).
107. Choi HJ, Cho HY, Ro H et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr. Nephrol. 26(11), 1981-1988 (2011).
108. Swierczewska M, Ostalska-Nowicka D, Kempisty B, Szczepankiewicz A, Nowicki M. Polymorphic variants of MIF gene and prognosis in steroid therapy in children with idiopathic nephrotic syndrome. Acta Biochim. Pol. 61(1), 67-75 (2014).
109. Tong X, He J, Liu S et al. Macrophage migration inhibitory factor-173G/C gene polymorphism increases the risk of renal disease: a meta-analysis. Nephrology (Carlton) 20(2), 68-76 (2015).
110. Chomarat P, Banchereau J, Miossec P. Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis. Arthritis Rheum. 38(8), 1046-1054 (1995).
111. Youn YS, Lim HH, Lee JH. The clinical characteristics of steroid responsive nephrotic syndrome of children according to the serum immunoglobulin e levels and cytokines. Yonsei Med. J. 53(4), 715-722 (2012).
112. Salsano ME, Graziano L, Luongo I, Pilla P, Giordano M, Lama G. Atopy in childhood idiopathic nephrotic syndrome. Acta Paediatr. 96(4), 561-566 (2007).
113. Neuhaus TJ, Wadhwa M, Callard R, Barratt TM. Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin. Exp. Immunol. 100(3), 475-479 (1995).
114. Printza N, Papachristou F, Tzimouli V, Taparkou A, Kanakoudi-Tsakalidou F. IL-18 is correlated with type-2 immune response in children with steroid sensitive nephrotic syndrome. Cytokine 44(2), 262-268 (2008).
115. Acharya B, Shirakawa T, Pungky A et al. Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in indonesian children with minimal change nephrotic syndrome. Am. J. Nephrol. 25(1), 30-35 (2005).
116. Kobayashi Y, Arakawa H, Suzuki M, Takizawa T, Tokuyama K, Morikawa A. Polymorphisms of interleukin-4-related genes in Japanese children with minimal change nephrotic syndrome. Am. J. Kidney Dis. 42(2), 271-276 (2003).
117. Liu HM, Shen Q, Xu H, Yang Y. Signifcance of polymorphisms in variable number of tandem repeat region of interleukin-4 gene in recurrence of childhood steroid sensitive nephrotic syndrome. Zhonghua Er Ke Za Zhi 43(6), 431-433 (2005).
118. Rosenwasser LJ, Klemm DJ, Dresback JK et al. Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 25(Suppl. 2), 74-78; discussion 95-76 (1995).
119. Ikeuchi Y, Kobayashi Y, Arakawa H, Suzuki M, Tamra K, Morikawa A. Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome. Pediatr. Nephrol. 24(3), 489-495 (2009).
120. Tenbrock K, Schubert A, Stapenhorst L et al. Type I IgE receptor, interleukin 4 receptor and interleukin 13 polymorphisms in children with nephrotic syndrome. Clin. Sci. (Lond.) 102(5), 507-512 (2002).
121. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4(11), 2860-2867 (1990).
122. Rizk MK, El-Nawawy A, Abdel-Kareem E, Amer ES, El-Gezairy D, El-Shafei AZ. Serum interleukins and urinary microglobulin in children with idiopathic nephrotic syndrome. East Mediterr. Health J. 11(5-6), 993-1002 (2005).
123. Ostalska-Nowicka D, Smiech M, Jaroniec M et al. SOCS3 and SOCS5 mRNA expressions may predict initial steroid response in nephrotic syndrome children. Folia Histochem. Cytobiol. 49(4), 719-728 (2011).
124. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102(7), 1369-1376 (1998).
125. Mittal RD, Manchanda PK. Association of interleukin (IL)-4 intron-3 and IL-6-174 G/C gene polymorphism with susceptibility to end-stage renal disease. Immunogenetics 59(2), 159-165 (2007).
126. Franchimont D, Louis E, Dupont P et al. Decreased corticosensitivity in quiescent Crohn's disease: an ex vivo study using whole blood cell cultures. Dig. Dis. Sci. 44(6), 1208-1215 (1999).
127. Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol. Immunother. 46(5), 239-244 (1998).
128. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92(10), 3943-3948 (1998).
129. Liu LL, Qin Y, Cai JF et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139(3), 314-320 (2011).
130. Araya C, Diaz L, Wasserfall C et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24 (9), 1691-1698 (2009).
131. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 16 (8), 1437-1442 (2002).
132. De Paz B, Alperi-Lopez M, Ballina-Garcia FJ, Prado C, Gutierrez C, Suarez A. Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J. Rheumatol. 37(12), 2502-2510 (2010).
133. Bantis C, Heering PJ, Aker S, Klein-Vehne N, Grabensee B, Ivens K. Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis. Kidney Int. 66(1), 288-294 (2004).
134. Chapman MS, Qu N, Pascoe S et al. Isolation of differentially expressed sequence tags from steroid-responsive cells using mRNA differential display. Mol. Cell Endocrinol. 108(1-2), R1-R7 (1995).
135. Nishibori Y, Katayama K, Parikka M et al. Glcci1 defciency leads to proteinuria. J. Am. Soc. Nephrol. 22(11), 2037-2046 (2011).
136. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011).
137. Cheong HI, Kang HG, Schlondorff J. GLCCI1 single nucleotide polymorphisms in pediatric nephrotic syndrome. Pediatr. Nephrol. 27(9), 1595-1599 (2012).
138. Farrell RJ, Menconi MJ, Keates AC, Kelly CP. P-glycoprotein-170 inhibition signifcantly reduces cortisol and ciclosporin effux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol. Ther. 16(5), 1021-1031 (2002).
139. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Seminars Cancer Biol. 8(3), 135-142 (1997).
140. Wasilewska A, Zoch-Zwierz W, Pietruczuk M, Zalewski G. Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr. Nephrol. 21(9), 1274-1280 (2006).
141. Wasilewska AM, Zoch-Zwierz WM, Pietruczuk M. Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. Eur. J. Pediatr. 165(12), 839-844 (2006).
142. Funaki S, Takahashi S, Wada N, Murakami H, Harada K. Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome. Pediatr. Int. 50(2), 159-161 (2008).
143. Stachowski J, Zanker CB, Runowski D et al. Resistance to therapy in primary nephrotic syndrome: Effect of MDR1 gene activity. Pol. Merkur. Lekarski.8(46), 218-221 (2000).
144. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB. Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum. Genet. 77(2), 142-144 (1987).
145. Hoffmeyer S, Burk O, Vonrichter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
146. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. 69(3), 169-174. (2001).
147. Kim RB, Leake BF, Choo EF et al. Identifcation of functionally variant MDR1 alleles among european americans and african americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
148. Wasilewska A, Zalewski G, Chyczewski L, Zoch-Zwierz W. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr. Nephrol. 22(1), 44-51 (2007).
149. Jafar T, Prasad N, Agarwal V et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol. Dial. Transplant. 26(12), 3968-3974 (2011).
150. Chiou YH, Wang LY, Wang TH, Huang SP. Genetic polymorphisms infuence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr. Nephrol. 27(9), 1511-1517 (2012).
151. Youssef DM, Attia TA, El-Shal AS, Abduelometty FA. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene 530(2), 201-207 (2013).
152. Cizmarikova M, Podracka L, Klimcakova L et al. MDR1 polymorphisms and idiopathic nephrotic syndrome in slovak children: preliminary results. Med. Sci. Monit. 21, 59-68 (2015).
153. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
154. Miura M, Satoh S, Inoue K et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 73(11), 1052-1059 (2008).